» Articles » PMID: 34697644

The Role of PPAR-γ in Allergic Disease

Overview
Date 2021 Oct 26
PMID 34697644
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: The incidence of allergic diseases such as asthma, rhinitis and atopic dermatitis has risen at an alarming rate over the last century. Thus, there is a clear need to understand the critical factors that drive such pathologic immune responses. Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a nuclear receptor that has emerged as an important regulator of multiple cell types involved in the inflammatory response to allergens; from airway epithelial cells to T Helper (TH) cells.

Recent Findings: Initial studies suggested that agonists of PPAR-γ could be employed to temper allergic inflammation, suppressing pro-inflammatory gene expression programs in epithelial cells. Several lines of work now suggest that PPAR-γ plays an essential in promoting 'type 2' immune responses that are typically associated with allergic disease. PPAR-γ has been found to promote the functions of TH2 cells, type 2 innate lymphoid cells, M2 macrophages and dendritic cells, regulating lipid metabolism and directly inducing effector gene expression. Moreover, preclinical models of allergy in gene-targeted mice have increasingly implicated PPAR-γ in driving allergic inflammation. Herein, we highlight the contrasting roles of PPAR-γ in allergic inflammation and hypothesize that the availability of environmental ligands for PPAR-γ may be at the heart of the rise in allergic diseases worldwide.

Citing Articles

Identification of telomere-related gene subtypes and prognostic signatures in osteosarcoma.

Song Z, Yu W, Yin X Front Pharmacol. 2025; 16:1545913.

PMID: 40070565 PMC: 11893505. DOI: 10.3389/fphar.2025.1545913.


Immune-endocrine crossroads: the impact of nuclear receptors in Tuberculosis and Chagas disease.

Perez A, Bottasso O, Santucci N Front Endocrinol (Lausanne). 2025; 16:1538376.

PMID: 39991733 PMC: 11842248. DOI: 10.3389/fendo.2025.1538376.


Targeting TCMR-associated cytokine genes for drug screening identifies PPARγ agonists as novel immunomodulatory agents in transplantation.

Hu L, Zhang X, Zhang W, Jin S, Zhao J, Zheng J Front Immunol. 2025; 16:1539645.

PMID: 39911401 PMC: 11794815. DOI: 10.3389/fimmu.2025.1539645.


The role of PPAR in fungal keratitis.

Zhou H, Zhang H, Bi M, Zhang W Front Immunol. 2025; 15:1454463.

PMID: 39763659 PMC: 11700800. DOI: 10.3389/fimmu.2024.1454463.


Molecular mechanisms of obesity predisposes to atopic dermatitis.

Shang D, Zhao S Front Immunol. 2024; 15:1473105.

PMID: 39564133 PMC: 11574713. DOI: 10.3389/fimmu.2024.1473105.


References
1.
Law R, Meehan W, Xi X, Graf K, Wuthrich D, Coats W . Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996; 98(8):1897-905. PMC: 507630. DOI: 10.1172/JCI118991. View

2.
Bishop-Bailey D, Warner T . PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. FASEB J. 2003; 17(13):1925-7. DOI: 10.1096/fj.02-1075fje. View

3.
Ho P, Steinman L . The aryl hydrocarbon receptor: a regulator of Th17 and Treg cell development in disease. Cell Res. 2008; 18(6):605-8. DOI: 10.1038/cr.2008.63. View

4.
Brenner B, Holmes T, Mazal B, Camargo Jr C . Relation between phase of the menstrual cycle and asthma presentations in the emergency department. Thorax. 2005; 60(10):806-9. PMC: 1747196. DOI: 10.1136/thx.2004.033928. View

5.
Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P . PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006; 55(9):1341-9. PMC: 1860011. DOI: 10.1136/gut.2006.093484. View